Apitope appoints Dr. Martin Sims as Research Director
Apitope International N.V. announced that Dr. Martin Sims will join the Senior Management team as Research Director with immediate effect. Martin will be responsible for Apitope’s research operations, working closely with the Chief Scientific Officer (CSO), Professor David Wraith, to guide the company’s overall scientific strategy.
Martin will focus on the strategic scientific planning for the generation and validation of novel targets within the autoimmune and allergic diseases therapeutic areas. His key responsibilities include portfolio development; overseeing the creation, development, design and commercial implementation of the company’s research programmes; and building partnerships and relationships with the global scientific community.
Martin brings with him over twenty years’ experience of drug discovery research in the pharmaceutical industry, with a strong background in immunology. Prior to joining Apitope, Martin held a number of roles at GlaxoSmithKline from 2000 to 2010, most recently as a Director in Medicines Discovery and Development. He has led multiple projects, in both therapeutic antibody and NCE projects in the inflammation and autoimmune therapeutic areas. Martin was Head of the Immunology Department and then the Rheumatoid Arthritis Pharmacology Department in the Respiratory and Inflammation Drug Discovery group at GlaxoSmithKline between 2002 and 2007; a Section Head in GlaxoWellcome 1995-2000 and a Research Scientist at the Wellcome Foundation in the period 1990 - 1995.
Other news from the department people
